Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

SEMA3A-mediated crosstalk between prostate cancer cells and tumor-associated macrophages promotes androgen deprivation therapy resistance

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1

References

  1. 1.

    Velez, E. M. et al. Comparative prognostic implication of treatment response assessments in mCRPC: PERCIST 1.0, RECIST 1.1, and PSA response criteria. Theranostics 10, 3254–3262 (2020).

    CAS  Article  Google Scholar 

  2. 2.

    Gillessen, S. et al. Management of patients with advanced prostate cancer: report of the advanced prostate cancer consensus conference 2019. Eur. Urol. 77, 508–547 (2020).

    CAS  Article  Google Scholar 

  3. 3.

    Di Mitri, D. et al. Re-education of tumor-associated macrophages by CXCR2 blockade drives senescence and tumor inhibition in advanced prostate cancer. Cell Rep. 28, 2156–2168.e5 (2019).

    Article  Google Scholar 

  4. 4.

    Casazza, A. et al. Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell 24, 695–709 (2013).

    CAS  Article  Google Scholar 

  5. 5.

    Ren, S. et al. Whole-genome and transcriptome sequencing of prostate cancer identify new genetic alterations driving disease progression. Eur. Urol. 73, 322–339 (2018).

    CAS  Article  Google Scholar 

  6. 6.

    Wang, C. et al. Blocking the feedback loop between neuroendocrine differentiation and macrophages improves the therapeutic effects of enzalutamide (MDV3100) on prostate cancer. Clin. Cancer Res. 24, 708–723 (2018).

    CAS  Article  Google Scholar 

  7. 7.

    Noy, R. & Pollard, J. W. Tumor-associated macrophages: from mechanisms to therapy. Immunity 41, 49–61 (2014).

    CAS  Article  Google Scholar 

  8. 8.

    Murray, P. J. et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 41, 14–20 (2014).

    CAS  Article  Google Scholar 

  9. 9.

    Tse, B. W. C. et al. Neuropilin-1 is upregulated in the adaptive response of prostate tumors to androgen-targeted therapies and is prognostic of metastatic progression and patient mortality. Oncogene 36, 3417 (2017).

    CAS  Article  Google Scholar 

Download references

Acknowledgements

The National Natural Science Foundation of China (81472397 to S.R. and 81773154 to C.W.). The Top-level Clinical Discipline Project of Shanghai Pudong (PWYgf2018-03, C.W.). The Shanghai Natural Science Foundation (20ZR1449600, C.W.). The Leadership Program in Science and Technology of Beijing Municipal Science and Technology Commission (181100006318007, N.X.).

Author information

Affiliations

Authors

Corresponding authors

Correspondence to Fei Liu or Shancheng Ren.

Ethics declarations

Competing interests

The authors declare no competing interests.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Liu, F., Wang, C., Huang, H. et al. SEMA3A-mediated crosstalk between prostate cancer cells and tumor-associated macrophages promotes androgen deprivation therapy resistance. Cell Mol Immunol 18, 752–754 (2021). https://doi.org/10.1038/s41423-021-00637-4

Download citation

Search

Quick links